Nakagomi Takayuki, Takagi Toshinori, Beppu Mikiya, Yoshimura Shinichi, Matsuyama Tomohiro
Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
World J Stem Cells. 2019 Aug 26;11(8):452-463. doi: 10.4252/wjsc.v11.i8.452.
Ischemic stroke is a critical disease which causes serious neurological functional loss such as paresis. Hope for novel therapies is based on the increasing evidence of the presence of stem cell populations in the central nervous system (CNS) and the development of stem-cell-based therapies for stroke patients. Although mesenchymal stem cells (MSCs) represented initially a promising cell source, only a few transplanted MSCs were present near the injured areas of the CNS. Thus, regional stem cells that are present and/or induced in the CNS may be ideal when considering a treatment following ischemic stroke. In this context, we have recently showed that injury/ischemia-induced neural stem/progenitor cells (iNSPCs) and injury/ischemia-induced multipotent stem cells (iSCs) are present within post-stroke human brains and post-stroke mouse brains. This indicates that iNSPCs/iSCs could be developed for clinical applications treating patients with stroke. The present study introduces the traits of mouse and human iNSPCs, with a focus on the future perspective for CNS regenerative therapies using novel iNSPCs/iSCs.
缺血性中风是一种严重疾病,会导致诸如麻痹等严重的神经功能丧失。新型疗法的希望基于越来越多的证据表明中枢神经系统(CNS)中存在干细胞群体以及针对中风患者开发基于干细胞的疗法。尽管间充质干细胞(MSCs)最初是一种有前景的细胞来源,但在中枢神经系统损伤区域附近仅存在少数移植的间充质干细胞。因此,当考虑缺血性中风后的治疗时,中枢神经系统中存在和/或诱导产生的局部干细胞可能是理想的选择。在这种情况下,我们最近发现,损伤/缺血诱导的神经干细胞/祖细胞(iNSPCs)和损伤/缺血诱导的多能干细胞(iSCs)存在于中风后的人类大脑和中风后的小鼠大脑中。这表明iNSPCs/iSCs可用于开发治疗中风患者的临床应用。本研究介绍了小鼠和人类iNSPCs的特征,重点关注使用新型iNSPCs/iSCs进行中枢神经系统再生治疗的未来前景。